Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis?

Abstract

Background: Calcium dobesilate (CaD) is a member of the synthetic veno-active drug family. Only a small number of reports are available that describe the micro-angiogenic effects of CaD in the current literature.

Material and methods: The antiangiogenic potential of CaD was compared with bevacizumab (Bb), which is a potent angiogenesis inhibitor, in a chick chorioallantoic membrane model. Four different concentrations (10-7, 10-6, 10-5, and 10-4 M) of drug pellet were prepared for each drug. Changes in vessel formation were scored and compared for each drug according to the previous literature.

Results: The antiangiogenic behavior of CaD was lower than Bb, despite the significant dose-dependent manner of escalation. The anti-angiogenic scores of CaD were determined as 0.20, 0.47, 0.66, 1.0 in 10-7, 10-6, 10-5, and 10-4 M concentrations, respectively (average score >0.5 was significant).

Conclusions: According to the data obtained, this agent should be used carefully for cases in which angiogenesis plays an important role in healing.

Figures

Figure 1

(A) Albumen aspirating (~5–6) ml via syringe. (B) Normal embryo development after the removal of eggshell.

Figure 2

(A) Placement of drug pellet (B) Evaluation of variations in capillary density around the drug pellets [Score 2] (×8).

Figure 3

Comparison of distribution of antiangiogenic scores at 10−6 M concentration of Bevacizumab and 10−7, 10−6, 10−5, and 10−4 M concentrations of Calcium Dobesilate.

Figure 4

Comparison of average antiangiogenic scores between 10−6, 10−5, 10−4 M concentrations of Bevacizumab and Calcium Dobesilate in a scatter graph.